ABSTRACT
INTRODUCTION
The Philadelphia chromosome can harbor one of several kinds of fusion genes between bcr and c-abl, and plays a major pathogenetic role for chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) 1 . The p190 bcr-abl fusion gene (e1a2) is detectable in 20-35% of patients with ALL 2, 3 . Patients shown to express the mRNA transcript encoding e1a2 have a poor prognosis, despite intensive treatment such as high-dose chemotherapy followed by hematopoietic stem-cell transplantation [2] [3] [4] . In addition, almost all of them 4 was very difficult even when we used established cell lines as target cells. Recently, we and others reported that gene transduction efficiencies of vesicular stomatitis virus (VSV)-pseudotyped lentiviral vectors, which were derived from human immunodeficiency virus type-1 (HIV), into patients' leukemia cells were much higher than those obtained using the MLV vector 17, 18 . Therefore, we have developed an Mz-expressing HIV vector targeting the p190-type bcr-abl (e1a2Mz) for the treatment of Ph + ALL. This e1a2Mz vector was designed to form an active secondary structure only in the presence of the p190-type bcr-abl fusion gene and not in their absence (Fig. 1A , B) 16 , and was found to digest successfully synthetic e1a2 oligonucleotide 16 . In this study, we have successfully transduced the e1a2Mz into Ph + ALL cells with a third-generation HIV vector system and examined the effect of this Mz on Ph + ALL cells and normal human hematopoietic progenitor cells.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From 6 informed consent. Mononuclear cells were purified from these samples by Ficoll-Hypaque methods as previously reported 18 . These cells were processed further to isolate CD34-positive cells (CD34 + CBC) using a MACS direct CD34 progenitor cell isolation kit (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's instructions.
After two rounds of isolation, more than 95% of cells were CD34-positive, as assessed by FCM. After transduction with the lentiviral vectors, CD34 + CBCs were cultured in IMDM supplemented with 10% BIT9500, a serum substitute (Stem Cell Technologies, Vancouver, Canada), 100 ng/mL stem cell factor (SCF, Genzyme, Cambridge, MA), 100 ng/mL thrombopoietin (Chemicon, Temecula, CA), and 100 ng/mL granulocyte-colony-stimulating factor (G-CSF, kindly provided by Chugai Pharmaceuticals Co. Ltd., Tokyo, Japan) for 14 days. To determine the colony-forming abilities of e1a2Mz-transduced CD34 + CBCs, a sample of cells (300 cells) was obtained immediately after the start of gene transduction and plated in IMDM containing 30% FBS, 1% bovine serum albumin, 1.2% methylcellulose and the following hematopoietic factors: 25 ng/mL SCF, 10 ng/mL interleukin-3 (kindly provided by Chugai Pharmaceuticals Co. Ltd.), 100 ng/mL interleukin-6 (kindly provided by Ajinomoto Co. Inc., Tokyo, Japan), 10 ng/mL G-CSF and 2 U/mL erythropoietin (kindly provided by Chugai Pharmaceuticals Co. Ltd.). Colony numbers were counted 14 days after transduction was performed.
Construction of e1a2Mz expression plasmids. The sequences and secondary structure of e1a2Mz were reported previously 16 and are shown in Fig. 1 . This e1a2Mz expression unit was inserted into a self-inactivating lentiviral vector plasmid, pHIV-ECD2, which was derived from pCS-CDF-EG-PRE and contains human CD2 (hCD2, provided by Health Science Research Resources Bank, Osaka, Japan) as a marker gene ( Fig. 2A) . We also constructed control plasmids to make control HIV vectors as described in Table 1 . A b2a2Mz-expression unit, which was used in our previous study 12 , was inserted into the pHIV-ECD2 as the e1a2Mz-expression unit. Lentiviral vector particles were produced as described previously
18
. Briefly, the pHIV-e1a2Mz or control plasmids were cotransfected with the third-generation packaging plasmid pMDLg/p.RRE (kindly provided from Cell Genesys), pRSV-rev, and pMD.G into 293T cells. Viral supernatants were harvested 48 and 72 hours after transfection, passed through 0.22 µm filters (Millipore, Bedford, MA), and concentrated by two rounds of ultracentrifugation. The viral pellet was resuspended in serum-free IMDM to obtain a 10,000-fold concentrate. Viral stocks were stored at -80˚C until assay, and viral titers were determined by the transduction of HeLa cells with serial dilutions followed by flow cytometry (FCM), ranging from 8x10 8 to 2x10 9 HeLa-transducing units per milliliter.
Inoculation of viral vectors. 2x10 5 human blood cells obtained as described above
were inoculated with e1a2Mz vector or control vectors for two hours at 37˚C in a CO 2 incubator. After inoculation at an MOI of 0.1 to 80, cells were washed and cultured in media as described above. To obtain CD2-expressing cells after transduction at low titers, cells were selected by magnetic beads method using a MACS CD2 MicroBead kit (Miltenyi Biotech) three days after transduction. (antisense). PCR products were examined by electrophoresis in a 2% agarose gel.
Detection of bcr-abl mRNA.
To quantify p190-type bcr-abl mRNA, cDNA synthesized from total RNA of Ph + ALL cells using an oligo (dT) primer as (Table 1) was also 100% in all cell lines (data not shown). Expression of the CD2 transgene was maintained over the entire period of the assay (data not shown). After transduction of the e1a2Mz vector, the survival rate of OM9;22 Ph + ALL cells began to decrease from day 7
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Effect of the e1a2 Mz on Ph
and was about 30% on day 14 ( , and did not affect the viability of Ph + ALL cell lines (data not shown).
In contrast, the viability of KOPN-57 and SUP-B15 Ph + ALL cells did not decrease upon e1a2Mz vector transduction, nor did that of the p190-type bcr-abl-negative K562 and NB4 cells (Fig. 3A, B) . To determine the mechanism of e1a2Mz-induced cell death, we performed an Annexin V assay to look for signs of apoptosis. In e1a2Mz-sensitive KOPN-30 cells, apoptotic cells began to appear seven days after e1a2Mz vector transduction and increased in number until day 14 ( Fig. 3C) . In other e1a2Mz-sensitive Ph + ALL cells, but not in e1a2Mz-resistant Ph + ALL or p190 type bcr-abl-negative cells, apoptosis was induced similarly by e1a2Mz vector transduction (data not shown).
Integration of the e1a2Mz vector.
Recently, X-linked severe combined immunodeficiency (SCID-X1) patients whose lymphocytes were transduced with a MLV vector have been reported to develop leukemia, and insertional mutagenesis is an important problem in the gene therapy using retroviral vectors 25 . In retroviral transduction, the number of integration sites/cell was reported to be increased at higher MOI (Fig. 4B) . The bcr-abl mRNA copy number in e1a2Mz-resistant cells, however, was higher than that in e1a2Mz-sensitive cells after e1a2Mz transduction (Fig. 4B) .
Titer escalation study. Because the insufficient decrease of bcr-abl mRNA was a possible mechanism of e1a2Mz resistance, we transduced e1a2Mz into KOPN57 and SUP-B15 cells at a higher MOI to observe the extent of the resistance by titer escalation. In KOPN57 cells, growth inhibition and a decrease in viability were observed in a dosedependent manner without any increase in non-specific toxicity (Fig. 5A) . In contrast, SUP- Similar to the results seen for Ph + cell lines, the transduction efficiency into these cells was almost 100% in all four samples three days after transduction (Fig. 6A) . At first, we examined the viability of primary leukemia cells in the same culture system as that used for cell lines. We could not determine clearly, however, whether e1a2Mz had any inhibitory effects because it was very difficult to culture these cells in our conventional liquid culture system: the number of live cells decreased continuously after the start of culture regardless of whether or not the e1a2Mz vectors were transduced. Therefore, we used a coculture system reported previously, in which a murine bone marrow stroma cell line was used as a source for . We counted the number of cobblestone formations on day 14 to 17 after transduction. In all of the experiments, a significant decrease of the size of CAs was observed upon transduction with the e1a2Mz vector. In addition, the number of CAs decreased in number after transduction with the e1a2MzL and e1a2MzR vectors together at an MOI of 10 for each vector (total MOI=20), but not with the other control vectors ( Fig. 6C and Table 2 ). However, we could not determine whether the CA formation would be inhibited completely by e1a2Mz transduction because all of the CA from untransduced or control vector-transduced cells also eventually disappeared after approximately 21 days from the start of the assay as those from the e1a2Mz-transduced cells did in 14 to 17 days as above. As observed in the cell lines, e1a2Mz transduction of primary leukemia cells induced an increase in apoptosis (Fig. 6D) .
Effect of the e1a2 Mz on CD34 + CBC. In K562 and NB4 cells, whose survival is not dependent upon p190-type bcr-abl, transduction with e1a2Mz did not affect viability and (Fig. 3A, B) , suggesting that there is little non-specific cytotoxicity associated with the procedure. To evaluate further the safety of the e1a2Mz vector, we transduced it into normal human CD34 + CBCs. Almost all cells transduced with the e1a2Mz or control vectors expressed CD2 (Fig. 7A) . In these cells, we also confirmed e1a2Mz expression by RT-PCR (data not shown). The viability of CD34 + CBCs did not decrease after transduction with the e1a2Mz or control vectors (Fig. 7B) . In addition, the number and composition of colonies were not affected by e1a2Mz transduction (Fig. 7C ). . Therefore, we adopted a third-generation HIV(VSV) vector system and successfully transduced an e1a2 Mz vector into five different Ph + ALL cell lines and two control cell lines with 100% efficiency (Fig. 2B, C) . Moreover, we could transduce those vectors into primary leukemia cells from Ph + ALL patients with the same efficiency (Fig. 6A) . This is the first report of such a high transduction efficiency into [31] [32] [33] . In addition, however, the transduction efficiencies observed in this study were higher than those obtained in a previous report from our laboratory (52% to 95%) 18 which also employed a third-generation HIV vector with the central DNA flap sequence. This difference was probably due to the use of the EF-1α promoter in this study, which has been reported to work more strongly in lymphoid cells than the CMV promoter used in the previous study 34 .
DISCUSSION
We successfully demonstrated that the e1a2Mz efficiently induced cell death in the Ph + ALL cell lines OM9;22, KOPN-30 and KOPN-72 (Fig. 3) . These cytotoxic effects were thought to be e1a2Mz-dependent, because transduction of any control vectors, including vectors harboring only left or right arm of the e1a2Mz or b2a2Mz, did not affect the survival of these cells. In addition, we demonstrated that transduction of the e1a2Mz vector inhibited cobblestone area formation of primary Ph + ALL cells (Fig. 6C , Table 2 ). Furthermore, the growth of these cells was inhibited not only upon transduction of the e1a2Mz vector, which encoded both the left and right arms of the e1a2Mz, but also with cotransduction of the e1a2MzL and e1a2MzR vectors, which encoded only the left or right arm, respectively ( (Fig. 3B) , although e1a2Mz was expressed efficiently in these cells (Fig. 4A) and no mutation existed in the e1a2Mz-targeting sequence of their bcr-abl fusion genes. We confirmed a decrease in bcr-abl mRNA in these cells, but the amount of residual bcr-abl mRNA in these cells was higher than that in e1a2Mz-sensitive cells (Fig. 4B) , suggesting that the amount of undigested bcr-abl mRNA was high enough to make the cells functionally e1a2Mz-resistant. Therefore, we transduced the cells with a higher titer of e1a2Mz vector to increase the intracellular digestion of bcr-abl mRNA. As expected, the viability of KOPN-57 cells decreased in a titer-dependent manner (Fig. 5A ), but that of SUP-B15 cells did not decrease, despite the escalation of viral titer (Fig. 5B) . We could not elucidate the cause of e1a2Mz resistance in SUP-B15 cells; it is possible, however, that the expression of other oncogenes besides bcr-abl contributes autonomously to the proliferation of this cell line.
Importantly, the e1a2Mz was expressed in but did not affect the survival of both leukemia cell lines not harboring a p190-type bcr-abl fusion gene (Fig. 3B) , and normal hematopoietic progenitor cells (Fig. 7B, C) . These results strongly suggest that transduction of e1a2Mz with our lentiviral vector system would be a secure as well as effective system for use in the clinical treatment of Ph + ALL. . These reagents and vectors will be useful in the development of a selective transduction system to deliver e1a2Mz into target cells, potentially allowing the establishment of effective in vivo gene therapy using e1a2Mz.
In conclusion, we have demonstrated the specific cytocidal effect of e1a2Mz on Ph + ALL cells using a third-generation lentiviral vector system. This is the first report demonstrating the cytotoxic effect of a ribozyme on Ph + ALL cells without any cytotoxicity to normal hematopoietic progenitor cells during in vitro observation period. Therefore, the e1a2Mz is considered to be a useful tool for gene therapy of Ph + ALL.
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